Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1803 |
GNF-5
GNF 5 |
SARS-CoV; Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Microbiology/Virology; Tyrosine Kinase/Adaptors |
GNF-5是 Bcr-Abl 的特异性非 ATP 竞争性抑制剂,IC50为0.22uM。它是 GNF-2 的类似物,具有改进的药代动力学特性。 | |||
T3196 |
GNF-7
GNF7 |
Bcr-Abl; ACK; AChR | Angiogenesis; Cytoskeletal Signaling; Neuroscience; Tyrosine Kinase/Adaptors |
GNF-7 是一种多重激酶抑制剂。它对ACK1和GCK 具有抑制活性,IC50分别为 25 nM 和 8 nM。它是一种 Bcr-Abl 的抑制剂,对 Bcr-AblWT 和 Bcr-AblT315I 作用的IC50值分别为 133 nM 和 61 nM。它可用于研究血液恶性肿瘤。 | |||
T22553 |
Adaphostin
1-Adamantyl 4-((2,5-Dihydroxybenzyl)Amino)Benzoate,NSC 680410 |
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Adaphostin (NSC-680410) 是 AG957 金刚烷酯,是一种 p210bcr/abl 抑制剂,可诱导 T 淋巴细胞白血病细胞系凋亡。它增加了 CLL B 细胞内活性氧的水平,对慢性和急性髓系白血病细胞具有显著的选择性活性。 | |||
T16545 |
Pivanex
Pivalyloxymethyl butyrate,AN-9 |
Apoptosis; HDAC; Bcr-Abl | Angiogenesis; Apoptosis; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Pivanex (Pivalyloxymethyl butyrate) 是丁酸的一种衍生物,是具有口服活性的 HDAC 抑制剂。Pivanex 通过下调 bcr-abl 蛋白增强凋亡。Pivanex 显示出抗转移和抗血管生成的活性。 | |||
T26625 |
AN-019
NRC-AN-019,NRC-019 |
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
AN-019 (NRC-019) 是一种 Bcr-Abl 激酶抑制剂, 具有抗肿瘤活性,可用于研究慢性粒细胞白血病(CML)和乳腺癌。 | |||
T72958 |
BCR-ABL-IN-7
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
BCR-ABL-IN-7 是一种 WT 和 T315I 突变体 ABL 激酶抑制剂。BCR-ABL-IN-7 有效抑制 WT 和 T315I 突变体 ABL 激酶的活性。BCR-ABL-IN-7 可以用于慢性髓系白血病 (CML) 的研究。 | |||
T22859 | Imatinib hydrochloride | Others | Others |
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and a number of other malignancies. | |||
T71313 |
BVB-808
|
||
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning int... |